Cardiovascular Diseases and Therapeutics

Biography

Biography: Ersin Akpinar

Abstract

Sustained high blood pressure (BP) is a leading risk factor for developing heart disease, stroke, and renal disease. Globally, over 1 billion people have hypertension. As populations age and adopt more sedentary lifestyles, the worldwide prevalence of hypertension will continue to rise towards 1.5 billion by 2025. The positive association between BP and cardiovascular disease (CVD) risk has been well established. Classification of BP levels into categories supports clinical decision making, public health surveillance, and public and private programmatic activities.

As substantial progress has been made in understanding the epidemiology, pathophysiology, and risk associated with hypertension, and a wealth of evidence exists to demonstrate that lowering blood pressure (BP) can substantially reduce premature morbidity and mortality, a great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) and by the European Society of Hypertension (ESH), as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the users in 2018 The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension.

A number of proven, highly effective, and well-tolerated lifestyle and drug treatment strategies can achieve this reduction in BP. Despite this, BP control rates remain poor worldwide and are far from satisfactory across Europe. Consequently, hypertension remains the major preventable cause of CVD and all-cause death globally and in our continent

What is new and what has changed in New 2018 Arterial Hypertension Guidelines? will be the main theme of this session.